New science, in plain language. Checked before you read a word.

Every two days we take 10 brand-new scholarly papers, screen each one for retractions and a live DOI, and rewrite them so a curious person can actually read them.

This screen checks process signals. It does not tell you the findings are true.

Get it free, every two days

Three papers free every issue. No spam. Leave in one click.

In this issue 10 papers · 3 free

01 Science A statistical test for the benefits of personalizing interventions Free
02 Science Roots navigate around decay regions by sensing local pH gradients Free
03 Nature Medicine Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial Free
04 Nature Architecture of the 8 MDa Hdr-Vhu-Fwd super-assembly in class I methanogens Subscribers
05 Nature Ancient feeding-related neuropeptides regulate alloparenting in ants Subscribers
06 Nature Communications High temperature Nb-Si alloys using data science: optimization of fracture toughness and high-temperature strength Subscribers
07 Proceedings of the National Academy of Sciences A phase oscillator model of cell cycles reveals nuclear density control in a branched fungal network Subscribers
08 Proceedings of the National Academy of Sciences The combinatorial innexin code of heterochannel electrical synapses governs synaptic function and is maintained by distinct cellular mechanisms Subscribers
09 Nature Medicine Bispecific 10E8.4/iMab broadly neutralizing antibody in people with or without HIV-1: a partially randomized phase 1 trial Subscribers
10 Nature Communications Preferential nitrogen retention characterizes current eutrophication in United States lakes Subscribers

The papers Read free

Science·9 July 2026

Zhaoqi Li, Emma Brunskill

A statistical test for the benefits of personalizing interventions

A new tool checks if giving people different, custom treatments works better than giving everyone the same single best option. It uses past data to make this check. The test keeps a low rate of false alarms. It was tried on data from job training, depression care, schools, and recommendation systems. In these tests, it worked well and beat other methods.

A new statistical test can show if custom treatments beat one-size-fits-all options.

The number: No key statistic identified
The caveat: This is a math tool, not a treatment itself. It does not test any single program directly on real people. It only checks old data, so it cannot prove personalizing will always work in new situations.

For your life: today, nothing. This is basic research.

Integrity screen: passed (3 checks) Checked 10 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Science). Read the source

Science·9 July 2026

Zhulatai Bao, Huihui Wang et al.

Roots navigate around decay regions by sensing local pH gradients

Plant roots can bend away from rotting plant material in soil, without ever touching it. Rotting plant matter is broken down by fungi and other microbes. This breakdown releases acids that spread through the soil and change how acidic the ground is nearby. Root cells sense this uneven acid pattern and use it to grow away from the decaying spot. The root does this by turning the chemical signal into a change inside its own cells that makes one side grow differently than the other, so the root curves away.

Roots can detect and steer away from rotting plant matter using acid signals in soil.

The number: No key statistic identified
The caveat: The abstract gives no sample sizes, plant types tested, or bending amounts. So it is hard to know how strong or common this effect is. This is basic plant biology research. It does not tell us how this might affect farming or crops grown in real fields.

For your life: today, nothing. This is basic research.

Integrity screen: passed (3 checks) Checked 10 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Science). Read the source

Nature Medicine·9 July 2026

G. Paul, H. Bjartmarz et al.

Human embryonic stem cell-derived dopaminergic cells for Parkinson’s disease: a phase 1/2 open-label trial

Doctors tried a new treatment for Parkinson's disease. It uses lab grown brain cells to replace cells the disease destroys. Eight people got the cell transplant into their brains. Seven finished a year of follow up. One person died from a lung infection. No safety problems came from the cells themselves. Most risks came from the drugs used to stop the body rejecting the new cells. Brain scans showed no signs of tumors forming.

A new cell transplant for Parkinson's disease looked safe in a small early trial.

The number: 8 people got the treatment; 7 of them completed 12 months of follow up.
The caveat: Only 8 people took part, so this cannot show if the treatment truly works. One person died from a lung infection during the trial. Doctors still need to watch patients for up to 36 months to see if benefits last.

For your life: nothing to act on yet. Early research, worth watching.

Integrity screen: passed (3 checks) Checked 10 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Medicine). Read the source

7 more papers are in the full issue.

The same screening, the full reading, every two days. 2 euros a month, or 20 a year, and you can leave in one click.

Nature·8 July 2026

Sophia Paul, Tomas C. Pascoa et al.